SNIPR 001
Alternative Names: SNIPR-001Latest Information Update: 14 Aug 2026
At a glance
- Originator SNIPR Biome
- Class Antibacterials; Gene therapies; Urinary anti-infective agents
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Escherichia coli infections
- Preclinical Sepsis; Urinary tract infections
Most Recent Events
- 12 Aug 2026 SNIPR Biome Aps completes enrolment in phase Ib/IIa trial in Escherichia coli infections (Prevention) in USA (PO) (NCT06938867)
- 03 Mar 2026 Efficacy, adverse events and pharmacokinetic data from a phase I trial in Escherichia coli infections released by SNIPR Biome
- 28 Jun 2025 No recent reports of development identified for preclinical development in Escherichia-coli-infections(Prevention) in Denmark (PO)